Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
How To Invest $1 Million In Retirement For Life-Long Income
09:00am, Saturday, 13'th Jan 2024
We outline an Income Strategy for creating a self-sufficient portfolio for retirees and income-focused investors with $1 million to generate a life-long income stream. We explain the benefits of gener
Bristol-Myers Squibb: Big Dividend Yield, Unloved Big-Pharma Deal
10:12am, Friday, 12'th Jan 2024
I discuss a cheap Big Pharma stock and its performance in the market. I provide an overview of the stock's history, including its R&D cycle, dividend and yield on cost history, and valuation. With Eli
Dividend Harvesting Portfolio Week 149: $14,900 Allocated, $1,316.50 In Projected Dividends
09:00am, Thursday, 11'th Jan 2024
Dividend Harvesting Portfolio Week 149: $14,900 Allocated, $1,316.50 In Projected Dividends
Bullish Continuation in '24? 3 Market Areas to Watch
02:17pm, Wednesday, 10'th Jan 2024
Will stocks continue into 2024? Stock Strategist Andrew Rocco shares his prediction and unveils 3 important market areas to monitor.
U.S. Wide-Moat Stocks On Sale - The January 2024 Heat Map
01:17pm, Wednesday, 10'th Jan 2024
Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating).
Bristol-Myers Squibb: I Went Looking For Value And Found A 4.63% Yield Also
10:15am, Wednesday, 10'th Jan 2024
Shares of Bristol-Myers Squibb Company have bottomed and offer an enticing valuation. Bristol-Myers Squibb has a highly profitable business, strong cash flow, and a low P/E ratio. Bristol-Myers is dep
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
08:01am, Wednesday, 10'th Jan 2024
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
Here's Why Bristol Myers Squibb (BMY) Fell More Than Broader Market
07:38pm, Tuesday, 09'th Jan 2024
Bristol Myers Squibb (BMY) concluded the recent trading session at $51.28, signifying a -0.98% move from its prior day's close.
Bristol-Myers CEO Says the Company Is in Transition
12:57pm, Tuesday, 09'th Jan 2024
Bristol-Myers CEO Christopher Boerner says the company is in transition, but he's excited about the strength of recent deals and drugs in their pipeline. He speaks on "Bloomberg Markets" from San Fran
Biotech ETFs Stage Solid Comeback at the Start of 2024
12:47pm, Tuesday, 09'th Jan 2024
The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-
Bristol Myers Squibb CEO: With KarXT we'll be able to deliver good accuracy without the side effects
08:35pm, Monday, 08'th Jan 2024
Bristol Myers Squibb CEO Christopher Boerner joins 'Mad Money' host Jim Cramer to talk recent acquisitions made by the company, what's ahead for BMY and much more.
We got a number of important drugs from the Celgene acquisition, says Bristol Myers Squibb CEO
08:14pm, Monday, 08'th Jan 2024
Bristol Myers Squibb CEO Christopher Boerner joins 'Mad Money' host Jim Cramer to talk recent acquisitions made by the company, whats ahead for BMY and much more.
Bristol-Myers CEO talks new acquisitions: 'We are writing the next chapter of this company'
07:03pm, Monday, 08'th Jan 2024
Bristol-Myers Squibb CEO Chris Boerner detailed the pharmaceutical giant's slew of recent acquisitions in a Monday interview with CNBC's Jim Cramer.
IPO watch 2024: Which new stocks will hit the market?
07:03am, Monday, 08'th Jan 2024
Among 2023 IPOs, one of the top performers was RayzeBio Inc. NASDAQ: RYZB, a biotech that's out of play now because it's being acquired by Bristol Myers Squibb Co. NYSE: BMY.
5 Relatively Secure And Cheap Dividend Stocks To Invest In - January 2024
09:30am, Saturday, 06'th Jan 2024
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering pr
